Business Wire

ANEXT-BANK

6.6.2024 07:40:34 CEST | Business Wire | Press release

Share
ANEXT Bank Reports a Surge in Regional and Global Presence Among Its MSME Customers

ANEXT Bank, a digital wholesale bank incorporated in Singapore and a wholly-owned subsidiary of Ant International, today reported a notable increase in regional and global presence among its micro, small and medium enterprises (MSMEs) customers. This is on the back of more than 2-fold growth in its total customer base over the past 12 months.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605859058/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

Facilitating MSMEs’ Business Expansion Regionally and Beyond

The bank observed a 6-fold year-on-year increase in the total amount of cross-border transactions facilitated for its increasing customer base from the region and beyond. The highest growth in the bank’s cross-border transactions was seen among MSMEs in the wholesale and retail trade, professional services, and information, communication, and technology sectors, aligning with Singapore's robust status as a global trade and financial hub. Furthermore, ANEXT Bank customers exhibited an expanding regional and global presence, with operations extending beyond Singapore into key markets such as the Chinese mainland, Hong Kong SAR, the United States and other Southeast Asian countries.

In addition to Singapore MSMEs expanding regionally and globally, ANEXT Bank saw a notable increase in the number of Foreign Business Owners (FBOs) with businesses incorporated in Singapore. As of 31 May 2024, nearly 31% of the bank’s customers are FBO from 78 nationalities such as from the Chinese mainland, Indonesia, Japan, Malaysia and South Korea. Through its embedded finance partners, ANEXT Bank is also serving an increasing number of foreign-incorporated businesses.

“It is heartening to witness how MSMEs are growing beyond their markets, especially micro and small businesses. Internationalisation is no longer a growth strategy limited to large corporations – through technology and innovation, MSMEs can now easily access global markets. As a digital bank headquartered in Singapore, we are well positioned to support when they are open to doing business with the world,” said Ms. Toh Su Mei, CEO of ANEXT Bank. “It takes grit and openness to grow beyond the familiar. We share that same spirit with MSMEs. As we celebrate two years of delivering innovative digital financial services, we remain committed to supporting more MSMEs embrace new possibilities and achieve their global aspirations.”

Serving the Underserved MSMEs

As of 31 May 2024, 69% of ANEXT Bank’s customers are micro businesses. Breaking down by product categories, 56% of loan customers and 80% of deposit customers are micro businesses. Over the past two years, 31% of ANEXT Bank’s customers started banking with the bank during their start-up stage.

From setting up a multi-currency business account for local and overseas transfers with no minimal balance, getting fuss-free unsecured financing with flexible repayment options, and investing with a fixed deposit account from just US$5,000 for as short as one month, all these can be easily achieved within minutes.

In the most recent financial year ending 31 December 2023, ANEXT Bank achieved remarkable financial milestones. The "loans to customers" surged by 434%, reaching S$222 million, while the "deposits balance" increased by approximately 368%, totalling S$295 million. Additionally, ANEXT Bank reported S$24.5 million in gross income, highlighting its robust ability to generate revenue from primary banking activities and demonstrating significant progress towards its mission of driving financial inclusion.

About ANEXT Bank

Incorporated in Singapore and regulated by the Monetary Authority of Singapore, ANEXT Bank is a digital wholesale bank providing innovative digital financial services to empower local and regional micro, small and medium enterprises (MSMEs) to future-proof their businesses through digital adoption, sustainable practices and global expansion.

Through continuous technology-driven innovation, ANEXT Bank is dedicated to accelerating fintech development and financial inclusion in Singapore and the region. Adopting an open and collaborative approach, ANEXT Bank believes in joining hands with industry partners and public sector agencies to provide SMEs with financial services that are simpler, safer and more rewarding.

ANEXT Bank is a wholly-owned subsidiary of Ant International.

For more information on ANEXT Bank, please visit www.ANEXT.com.sg.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240605859058/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release

Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye